Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties (Bravura)

Teva Pharmaceuticals

Status: Completed

Conditions: Parkinson's Disease

Treatments: Other: Bradykinesia subscale of UPDRS Motor Examination; Other: Bradykinesia UPDRS Motor Full Examination

Study type: Observational

Funder types: Industry

Identifiers

NCT00932581

PM105

Details and patient eligibility

About

The purpose of this study is to examine whether scores on questionnaires that rate how much Parkinson's Disease (PD) has slowed movements of the body differ when the order of the questions are changed. The consistency and accuracy of the questionnaires will also be examined. It is hypothesized that there will not be a difference.

Enrollment: 110 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or Female at least 30 years of age
2. Willing to be assessed using the motor examination section of the UPDRS and the SPES/SCOPA motor evaluation
3. Patients must be willing and able to give written informed consent prior to performing an study procedures
4. Be in the "ON" State (only for patients who fluctuate between "ON" and "OFF" states)

Exclusion criteria

1. Absence of bradykinesia at the time of assessment
2. Hoehn and Yahr stage not available from patient's chart or not assessed between 3 and 180 days prior to clinic visit
3. Has received and experimental drug within the last thirty (30) days

Trial design

110 participants in 2 patient groups

Full Exam

Description:

The first group will receive the full motor examination section in its original order.

Treatment:

Other: Bradykinesia UPDRS Motor Full Examination

Subscale

Description:

The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.

Treatment:

Other: Bradykinesia subscale of UPDRS Motor Examination